Genetic variation in the mitochondrial enzyme carbamyl-phosphate synthetase I predisposes children to increased pulmonary artery pressure following surgical repair of congenital heart defects: a validated genetic association study.
Increased pulmonary artery pressure (PAP) can complicate the postoperative care of children undergoing surgical repair of congenital heart defects. Endogenous NO regulates PAP and is derived from arginine supplied by the urea cycle. The rate-limiting step in the urea cycle is catalyzed by a mitochondrial enzyme, carbamoyl-phosphate synthetase I (CPSI). A well-characterized polymorphism in the gene encoding CPSI (T1405N) has previously been implicated in neonatal pulmonary hypertension. A consecutive modeling cohort of children (N=131) with congenital heart defects requiring surgery was prospectively evaluated to determine key factors associated with increased postoperative PAP, defined as a mean PAP>20 mmHg for at least 1h during the 48h following surgery measured by an indwelling pulmonary artery catheter. Multiple dimensionality reduction (MDR) was used to both internally validate observations and develop optimal two-variable through five-variable models that were tested prospectively in a validation cohort (N=41). Unconditional logistic regression analysis of the modeling cohort revealed that age (OR=0.92, p=0.01), CPSI T1405N genotype (AC vs. AA: OR=4.08, p=0.04, CC vs. AA: OR=5.96, p=0.01), and Down syndrome (OR=5.25, p=0.04) were independent predictors of this complex phenotype. MDR predicted that the best two-variable model consisted of age and CPSI T1405N genotype (p<0.001). This two-variable model correctly predicted 73% of the outcomes from the validation cohort. A five-variable model that added race, gender and Down's syndrome was not significantly better than the two-variable model. In conclusion, the CPSI T1405N genotype appears to be an important new factor in predicting susceptibility to increased PAP following surgical repair of congenital cardiac defects in children.
Canter
Jeffrey A
JA
Center for Human Genetics Research, Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, TN, USA. jeff.canter@vanderbilt.edu
Summar
Marshall L
ML
Smith
Heidi B
HB
Rice
Geraldine D
GD
Hall
Lynn D
LD
Ritchie
Marylyn D
MD
Motsinger
Alison A
AA
Christian
Karla G
KG
Drinkwater
Davis C
DC
Scholl
Frank G
FG
Dyer
Karrie L
KL
Kavanaugh-McHugh
Ann L
AL
Barr
Frederick E
FE
D002222:Carbamoyl-Phosphate Synthase (Ammonia) / Q000235:genetics*; D015331:Cohort Studies; D004247:DNA / Q000097:blood / Q000235:genetics; D017931:DNA Primers; D004314:Down Syndrome / Q000453:epidemiology; D005260:Female; D014644:Genetic Variation; D006330:Heart Defects, Congenital / Q000601:surgery*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000453:epidemiology*; D007223:Infant; D008297:Male; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D011183:Postoperative Complications / Q000503:physiopathology*; D015203:Reproducibility of Results
D017931:DNA Primers; D004247:DNA; D002222:Carbamoyl-Phosphate Synthase (Ammonia)